Form 4: Flagship Pioneering Acquires Foghorn Therapeutics Warrants

Flagship Pioneering entities acquired over 4.4 million warrants in Foghorn Therapeutics, including pre-funded and series warrants with potential price resets, as part of a registered direct offering.

Summary

• Flagship Pioneering Fund VII, L.P. acquired warrants to purchase an aggregate of 4,470,936 shares of Foghorn Therapeutics Inc. common stock.
• The transaction is scheduled for January 13, 2026, as part of a registered direct offering by Foghorn Therapeutics.
• The warrants consist of 2,235,468 Pre-Funded Warrants, 1,117,734 Series 1 Warrants, and 1,117,734 Series 2 Warrants.
• The purchase price for the Pre-Funded Warrant and accompanying Series Warrants was $6.7099.
• Pre-Funded Warrants have an exercise price of $0.0001 and expire on January 13, 2046.
• Series 1 Warrants have an initial exercise price of $13.42 and expire on June 30, 2027.
• Series 2 Warrants have an initial exercise price of $20.13 and expire on December 31, 2030.
• The Series Warrants include a reset mechanism: if Foghorn issues capital stock for capital raising below $13.42 per share before June 30, 2027, the exercise price will reset to the midpoint between the initial price and the lowest weighted-average price, but not below $6.71 per share.
• Flagship Pioneering, LLC and related entities, including Noubar B. Afeyan, Ph.D., are considered directors by deputization due to Douglas G. Cole's board representation.

Sentiment

Score: 7

Explanation: The filing indicates a significant capital infusion for Foghorn Therapeutics from a major institutional investor, which is generally positive for a biotech company. However, the warrant reset mechanism introduces potential future dilution risks for existing shareholders, balancing the overall sentiment.

Positives

• A significant investment by a major institutional investor (Flagship Pioneering) indicates confidence in Foghorn Therapeutics' long-term potential.
• The registered direct offering provides capital to Foghorn Therapeutics, strengthening its financial position.
• The long expiration dates on the Pre-Funded Warrants (2046) and Series 2 Warrants (2030) provide flexibility for Flagship Pioneering.

Negatives

• The warrant reset mechanism for Series Warrants could lead to dilution for existing shareholders if Foghorn raises capital at a lower price in the future.
• The initial exercise prices for Series 1 ($13.42) and Series 2 ($20.13) warrants are significantly higher than the purchase price of $6.7099 for the Pre-Funded and accompanying Series Warrants, suggesting a premium for future upside.

Risks

• Dilution Risk: The Series Warrants' exercise price reset mechanism could lead to increased dilution for existing shareholders if Foghorn Therapeutics conducts future capital raises at a lower valuation (below $13.42 per share) before June 30, 2027.
• Market Price Volatility: The value of the warrants and the underlying common stock is subject to market fluctuations and the company's performance.
• Exercise Price Risk: If Foghorn's stock price does not rise above the exercise prices of the Series Warrants, Flagship Pioneering may not exercise them, or their value may diminish.

Future Outlook

The filing indicates a future capital raise by Foghorn Therapeutics through a registered direct offering, with warrants exercisable at various future dates, suggesting a long-term investment horizon for Flagship Pioneering. The warrant reset mechanism implies potential future capital raising activities by Foghorn Therapeutics.

Management Comments

• Douglas G. Cole, a Managing Partner at Flagship Pioneering, serves on the board of directors of the Issuer and has been deputized to represent the Reporting Persons on the board of directors of the Issuer.
• By virtue of Mr. Cole's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the 'Exchange Act'), each of the Reporting Persons may be deemed directors by deputization of the Issuer.
• This filing shall not be deemed an admission that any Reporting Person is a beneficial owner of the securities reported in this filing for purposes of Section 16 of the Exchange Act or otherwise, or is subject to Section 16 of the Exchange Act, and each Reporting Person disclaims beneficial ownership of these securities, except to the extent of such Reporting Person's pecuniary interest therein, if any.

Industry Context

This transaction represents a significant capital infusion for a biotechnology company (Foghorn Therapeutics) from a prominent life sciences venture capital firm (Flagship Pioneering). Such investments are common in the biotech sector, where companies often require substantial funding for research, development, and clinical trials. The structure with warrants and a reset mechanism is a common way for investors to gain upside potential while providing capital.

Comparison to Industry Standards

• The acquisition of warrants by a major institutional investor like Flagship Pioneering is a standard financing mechanism in the biotech industry, often seen in registered direct offerings or private placements to secure capital for R&D-intensive companies like Foghorn Therapeutics.
• The inclusion of a warrant exercise price reset clause, while beneficial to the investor, is a common feature in such deals, designed to protect the investor's downside in subsequent dilutive financing rounds, similar to terms seen in venture debt or structured equity deals for early to mid-stage biotech firms.
• The exercise prices and expiration dates for the warrants (e.g., Pre-Funded Warrants with a nominal exercise price and long term, Series Warrants with higher exercise prices and shorter terms) are typical for structured equity investments, balancing immediate capital needs with future upside potential.

Corporate Governance

Related Party Transactions

• Flagship Pioneering, LLC and its related funds (Flagship Pioneering Fund VII, L.P., etc.) are significant shareholders (10% owners) and have board representation (through deputization) in Foghorn Therapeutics Inc.
• The acquisition of warrants by Flagship Pioneering Fund VII, L.P. from Foghorn Therapeutics Inc. constitutes a transaction between related parties.

Stakeholder Impact

• Shareholders: Potential for dilution if Series Warrants are exercised, especially if the reset mechanism is triggered by future capital raises at lower prices. However, the capital infusion can support company growth, potentially benefiting shareholders long-term.
• Company (Foghorn Therapeutics): Receives capital from the registered direct offering, which can fund research, development, and operations.
• Flagship Pioneering: Increases its beneficial ownership and potential future stake in Foghorn Therapeutics, with structured terms to protect its investment.

Next Steps

• Foghorn Therapeutics will utilize the capital raised from this offering for its operations.
• Flagship Pioneering Fund VII, L.P. may exercise its warrants at the specified exercise prices and dates.
• Monitoring for any future capital raising activities by Foghorn Therapeutics, especially before June 30, 2027, to assess the impact of the warrant reset mechanism.

Key Dates

Recommendation

The filing details a significant capital raise through a registered direct offering, with a major institutional investor acquiring warrants. While the capital infusion is positive for Foghorn Therapeutics' operational runway, the warrant structure, particularly the reset mechanism, introduces potential future dilution for existing shareholders. The long-term nature of some warrants suggests confidence, but the immediate impact on share price is likely to be neutral to slightly negative due to the potential for future dilution and the pricing of the offering. Investors should hold and monitor the company's progress and future capital raising activities.

Keywords

Foghorn Therapeutics, FHTX, Flagship Pioneering, Warrants, Registered Direct Offering, SEC Form 4, Beneficial Ownership, Biotechnology, Capital Raise, Dilution, Insider Transaction